These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19015387)

  • 1. Looking at lithium: molecular moods and complex behaviour.
    Beaulieu JM; Caron MG
    Mol Interv; 2008 Oct; 8(5):230-41. PubMed ID: 19015387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A beta-arrestin 2 signaling complex mediates lithium action on behavior.
    Beaulieu JM; Marion S; Rodriguiz RM; Medvedev IO; Sotnikova TD; Ghisi V; Wetsel WC; Lefkowitz RJ; Gainetdinov RR; Caron MG
    Cell; 2008 Jan; 132(1):125-36. PubMed ID: 18191226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycogen synthase kinase-3 is essential for β-arrestin-2 complex formation and lithium-sensitive behaviors in mice.
    O'Brien WT; Huang J; Buccafusca R; Garskof J; Valvezan AJ; Berry GT; Klein PS
    J Clin Invest; 2011 Sep; 121(9):3756-62. PubMed ID: 21821916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Akt/GSK3 signaling in the action of psychotropic drugs.
    Beaulieu JM; Gainetdinov RR; Caron MG
    Annu Rev Pharmacol Toxicol; 2009; 49():327-47. PubMed ID: 18928402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Akt-GSK-3 signaling cascade in the actions of dopamine.
    Beaulieu JM; Gainetdinov RR; Caron MG
    Trends Pharmacol Sci; 2007 Apr; 28(4):166-72. PubMed ID: 17349698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deletion of GSK3β in D2R-expressing neurons reveals distinct roles for β-arrestin signaling in antipsychotic and lithium action.
    Urs NM; Snyder JC; Jacobsen JP; Peterson SM; Caron MG
    Proc Natl Acad Sci U S A; 2012 Dec; 109(50):20732-7. PubMed ID: 23188793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior.
    Beaulieu JM; Sotnikova TD; Marion S; Lefkowitz RJ; Gainetdinov RR; Caron MG
    Cell; 2005 Jul; 122(2):261-73. PubMed ID: 16051150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clozapine and lithium require Caenorhabditis elegans β-arrestin and serum- and glucocorticoid-inducible kinase to affect Daf-16 (FOXO) localization.
    Weeks KR; Dwyer DS; Aamodt EJ
    J Neurosci Res; 2011 Oct; 89(10):1658-65. PubMed ID: 21732403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Not only lithium: regulation of glycogen synthase kinase-3 by antipsychotics and serotonergic drugs.
    Beaulieu JM
    Int J Neuropsychopharmacol; 2007 Feb; 10(1):3-6. PubMed ID: 16784549
    [No Abstract]   [Full Text] [Related]  

  • 10. Lithium down-regulates tau in cultured cortical neurons: a possible mechanism of neuroprotection.
    Rametti A; Esclaire F; Yardin C; Cogné N; Terro F
    Neurosci Lett; 2008 Mar; 434(1):93-8. PubMed ID: 18289787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lithium pharmacodynamics and pharmacogenetics: focus on inositol mono phosphatase (IMPase), inositol poliphosphatase (IPPase) and glycogen sinthase kinase 3 beta (GSK-3 beta).
    Serretti A; Drago A; De Ronchi D
    Curr Med Chem; 2009; 16(15):1917-48. PubMed ID: 19442155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lithium Pharmacology and a Potential Role of Lithium on Methamphetamine Abuse and Dependence.
    Kitanaka N; Hall FS; Uhl GR; Kitanaka J
    Curr Drug Res Rev; 2019; 11(2):85-91. PubMed ID: 31875781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lithium, a potential protective drug in Alzheimer's disease.
    Engel T; Goñi-Oliver P; Gómez de Barreda E; Lucas JJ; Hernández F; Avila J
    Neurodegener Dis; 2008; 5(3-4):247-9. PubMed ID: 18322403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders.
    Forlenza OV; De-Paula VJ; Diniz BS
    ACS Chem Neurosci; 2014 Jun; 5(6):443-50. PubMed ID: 24766396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective disruption of dopamine D2-receptors/beta-arrestin2 signaling by mood stabilizers.
    Del' Guidice T; Beaulieu JM
    J Recept Signal Transduct Res; 2015 Jun; 35(3):224-32. PubMed ID: 26459714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs.
    Gould TD; Manji HK
    Neuropsychopharmacology; 2005 Jul; 30(7):1223-37. PubMed ID: 15827567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Advances in the Pharmacology and Toxicology of Lithium: A Neurobiologically Oriented Overview.
    Bortolozzi A; Fico G; Berk M; Solmi M; Fornaro M; Quevedo J; Zarate CA; Kessing LV; Vieta E; Carvalho AF
    Pharmacol Rev; 2024 May; 76(3):323-357. PubMed ID: 38697859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of neuropsychiatric drugs on glycogen synthase kinase-3 signaling.
    Sutton LP; Rushlow WJ
    Neuroscience; 2011 Dec; 199():116-24. PubMed ID: 22001305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lithium for schizophrenia: supporting evidence from a 12-year, nationwide health insurance database and from Akt1-deficient mouse and cellular models.
    Luo DZ; Chang CY; Huang TR; Studer V; Wang TW; Lai WS
    Sci Rep; 2020 Jan; 10(1):647. PubMed ID: 31959776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Psychotropic drugs and the involvement of the Akt/GSK3 signalling pathway in mental illnesses].
    Del'Guidice T; Beaulieu JM
    Med Sci (Paris); 2010; 26(6-7):647-51. PubMed ID: 20619169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.